AdvaMed: The invention after the invention

In January 2018, medical device manufacturers encountered a familiar nuisance: a tax they had already spent years trying to remove. Congress had suspended the 2.3% device excise tax for 2016 and 2017. The suspension expired. Permanent repeal had not arrived. For a business planning research spending, an expiration date could matter almost as much as a laboratory result.

This is an entry into AdvaMed, the Washington trade association whose members make devices, diagnostic tests, imaging equipment, and digital health technologies. Its work begins wherever invention meets an institution with the power to delay it. A surgeon may want a tool. The manufacturer still needs to navigate regulatory review, payment policy, and the rules of the market where it hopes to sell.

First, make it work. Then, make it reachable.

AdvaMed occupies an unusual position in the medical technology business. It represents manufacturers, while arguing that policies supporting them will improve patient access. Its members compete for customers, investment, and clinical adoption. They can nevertheless share an interest in clearer review procedures or more predictable reimbursement. The association turns those overlapping interests into committees, policy proposals, and conversations with government.

That combination distinguishes it from a consultant hired to handle one company’s submission. AdvaMed works on conditions facing a sector. The Medical Device Manufacturers Association offers overlapping advocacy, and regional associations offer their own networks. Sometimes these organizations are allies: the device-tax campaign involved AdvaMed, MDMA, and other groups. Collective representation is a crowded business, too.

For an emerging company, the attraction is practical. AdvaMed Accel serves eligible firms with annual U.S. revenue below $100 million, including businesses still doing research and development before sales. Members receive the broader association’s benefits, purchasing discounts, and educational opportunities. A small team can encounter people who have already wrestled with the policy problem now sitting on its desk.

“AdvaMed® gives access and a flow of information that small companies would not have access to without significant time and expense.”

Martha Shadan · BrilliantStrings Therapeutics
Member testimonial published by AdvaMed

A founder can use that network with a concrete agenda: identify the coverage question, find the relevant educational session, and compare the problem with peers. A compliance team can start with the ethics code and training resources. The useful first step is choosing a problem that another member would recognize. Membership gives a company somewhere to take the question.

The tax that kept coming back

The tax campaign illustrates both the usefulness and the limits of that arrangement. The levy took effect in 2013 under the Affordable Care Act. Industry opponents argued that taxing sales burdened innovation, including companies that had revenue but no profit. Temporary suspensions provided relief without settling the question. Early efforts at permanent removal failed to deliver a durable result.

By December 2019, repeal became part of a broader year-end spending package. President Donald Trump signed it into law on December 20. AdvaMed and MDMA described the outcome as the product of roughly a decade of lobbying and bipartisan support. The legislative vehicle mattered. A policy campaign can accumulate supporters for years before a bill gives them a workable occasion to vote.

The result also carried a public cost. A December 2018 estimate by the Congressional Budget Office and Joint Committee on Taxation put foregone federal revenue from eliminating the tax at $1.6 billion in 2020 and $2.2 billion in 2021. Those figures describe a fiscal estimate. They do not measure patient benefit or establish how manufacturers spent their savings.

A standing organization has a standing bill

AdvaMed’s own economics are easier to inspect. Its 2024 tax filing reports $54,776,637 in revenue and $54,420,636 in expenses. Program-service revenue accounts for 98.4% of the total. Membership and non-dues activities support a continuing institution: staff expertise, policy engagement, conferences, and member services. These are annual operating figures, rather than the price of any single lobbying victory.

That institution also convenes people who might become customers, collaborators, or investors. The MedTech Conference offers company presentations and business partnering alongside policy discussion. For a founder, a useful introduction may be more immediate than a legislative campaign. Neither comes with a guaranteed commercial result.

Imaging joins. Data changes the rules.

AdvaMed has widened the subjects under its roof. In December 2023 it announced a medical imaging division, bringing in advocacy previously housed within the Medical Imaging & Technology Alliance. Companies included Bayer, GE HealthCare, Philips, and Siemens Healthineers. Patrick Hope, previously MITA’s executive director, led the new division. Expertise moved with the companies.

Digital technology has also changed what the association asks companies to consider. Revisions to its Code of Ethics took effect on November 1, 2025, adding guidance on data-driven technologies, privacy, and responsible data management. HealthStream supplies an online training course. The code offers a shared reference for conduct; implementing it remains work for each company.

The organization’s leadership reflects that work. President and CEO Scott Whitaker previously served as chief operating officer of the Biotechnology Innovation Organization and as chief of staff at the U.S. Department of Health and Human Services. His professional background runs through government, policy, and industry convening. Those are the institutions and relationships that a manufacturer encounters after the engineering team has something to show.

The negotiation continues

In July 2026, AdvaMed welcomed progress on the draft MDUFA VI agreement, which links industry user fees to FDA review commitments. FDA’s materials cover proposed goals for fiscal years 2028 through 2032. Congressional authorization remained ahead. The distinction matters to members making plans: a negotiated draft and an enacted program carry different levels of certainty.

The lesson a reader can copy is specific: map the institutions that must act before a product can reach its buyer, then identify which obstacles are shared. An association makes sense where pooled expertise and collective representation address those obstacles. It has less to offer a problem unique to one device. Weak evidence, an unsuitable product, or a hospital’s purchasing decision still demands company-level work. AdvaMed helps explain why a working invention needs so many people who never designed it.